Annual Total Liabilities
$494.51 M
-$122.18 M-19.81%
December 31, 2022
Summary
- As of March 10, 2025, SRNE annual total liabilities is $494.51 million, with the most recent change of -$122.18 million (-19.81%) on December 31, 2022.
- During the last 3 years, SRNE annual total liabilities has fallen by -$30.37 million (-5.79%).
- SRNE annual total liabilities is now -19.81% below its all-time high of $616.69 million, reached on December 31, 2021.
Performance
SRNE Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$654.65 M
+$67.17 M+11.43%
June 30, 2023
Summary
- As of March 10, 2025, SRNE quarterly total liabilities is $654.65 million, with the most recent change of +$67.17 million (+11.43%) on June 30, 2023.
- Over the past year, SRNE quarterly total liabilities has increased by +$67.17 million (+11.43%).
- SRNE quarterly total liabilities is now at all-time high.
Performance
SRNE Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
SRNE Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -19.8% | +11.4% |
| 3 y3 years | -5.8% | +11.4% |
| 5 y5 years | +119.8% | +11.4% |
SRNE Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -19.8% | at low | at high | +34.9% |
| 5 y | 5-year | -19.8% | +25.2% | at high | +71.0% |
| alltime | all time | -19.8% | >+9999.0% | at high | -100.0% |
Sorrento Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2023 | - | $654.65 M(+11.4%) |
| Mar 2023 | - | $587.48 M(+18.8%) |
| Dec 2022 | $494.51 M(-19.8%) | $494.51 M(+1.9%) |
| Sep 2022 | - | $485.41 M(-2.2%) |
| Jun 2022 | - | $496.37 M(-21.1%) |
| Mar 2022 | - | $629.44 M(+2.1%) |
| Dec 2021 | $616.69 M(+56.1%) | $616.69 M(-0.8%) |
| Sep 2021 | - | $621.46 M(+4.7%) |
| Jun 2021 | - | $593.39 M(+55.0%) |
| Mar 2021 | - | $382.73 M(-3.1%) |
| Dec 2020 | $395.09 M(-24.7%) | $395.09 M(-13.5%) |
| Sep 2020 | - | $456.80 M(+0.9%) |
| Jun 2020 | - | $452.85 M(-6.7%) |
| Mar 2020 | - | $485.33 M(-7.5%) |
| Dec 2019 | $524.88 M(+26.0%) | $524.88 M(-5.3%) |
| Sep 2019 | - | $554.21 M(+4.1%) |
| Jun 2019 | - | $532.43 M(+8.4%) |
| Mar 2019 | - | $491.36 M(+17.9%) |
| Dec 2018 | $416.59 M(+85.1%) | $416.59 M(+14.3%) |
| Sep 2018 | - | $364.40 M(+88.8%) |
| Jun 2018 | - | $193.06 M(-1.5%) |
| Mar 2018 | - | $196.01 M(-12.9%) |
| Dec 2017 | $225.00 M(-28.6%) | $225.00 M(-35.1%) |
| Sep 2017 | - | $346.48 M(+20.1%) |
| Jun 2017 | - | $288.57 M(+1.9%) |
| Mar 2017 | - | $283.12 M(-10.1%) |
| Dec 2016 | $315.08 M(+55.5%) | $315.08 M(+52.5%) |
| Sep 2016 | - | $206.56 M(-4.4%) |
| Jun 2016 | - | $216.18 M(+17.0%) |
| Mar 2016 | - | $184.82 M(-8.8%) |
| Dec 2015 | $202.58 M(+517.1%) | $202.58 M(+13.5%) |
| Sep 2015 | - | $178.51 M(+329.5%) |
| Jun 2015 | - | $41.56 M(+33.0%) |
| Mar 2015 | - | $31.26 M(-4.8%) |
| Dec 2014 | $32.83 M(+27.4%) | $32.83 M(-0.9%) |
| Sep 2014 | - | $33.14 M(+2.6%) |
| Jun 2014 | - | $32.30 M(+2.6%) |
| Mar 2014 | - | $31.46 M(+22.1%) |
| Dec 2013 | $25.77 M | $25.77 M(+262.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2013 | - | $7.10 M(+251.8%) |
| Jun 2013 | - | $2.02 M(+7.7%) |
| Mar 2013 | - | $1.87 M(+220.8%) |
| Dec 2012 | $584.20 K(+62.6%) | $584.20 K(+7.4%) |
| Sep 2012 | - | $544.20 K(+30.9%) |
| Jun 2012 | - | $415.70 K(+29.9%) |
| Mar 2012 | - | $320.00 K(-10.9%) |
| Dec 2011 | $359.30 K(-40.5%) | $359.30 K(-23.9%) |
| Sep 2011 | - | $472.00 K(+11.1%) |
| Jun 2011 | - | $425.00 K(-61.9%) |
| Mar 2011 | - | $1.12 M(+84.8%) |
| Dec 2010 | $604.00 K(+71.1%) | $604.00 K(+42.6%) |
| Sep 2010 | - | $423.50 K(+83.3%) |
| Jun 2010 | - | $231.10 K(+25.1%) |
| Mar 2010 | - | $184.70 K(-47.7%) |
| Dec 2009 | $353.10 K(+200.8%) | $353.10 K(+63.8%) |
| Sep 2009 | - | $215.60 K(+467.4%) |
| Jun 2009 | - | $38.00 K(-0.3%) |
| Mar 2009 | - | $38.10 K(-67.5%) |
| Dec 2008 | $117.40 K(+3457.6%) | $117.40 K(>+9900.0%) |
| Sep 2008 | - | $200.00(>+9900.0%) |
| Jun 2008 | - | $0.00(-100.0%) |
| Mar 2008 | - | $11.70 K(+254.5%) |
| Dec 2007 | $3300.00(-99.3%) | $3300.00(-17.5%) |
| Sep 2007 | - | $4000.00(-75.8%) |
| Jun 2007 | - | $16.50 K(-54.9%) |
| Mar 2007 | - | $36.60 K(-92.2%) |
| Dec 2006 | $471.80 K(+1351.7%) | $471.80 K(+1351.7%) |
| Sep 2006 | - | $32.50 K(0.0%) |
| Jun 2006 | - | $32.50 K(0.0%) |
| Mar 2006 | - | $32.50 K(0.0%) |
| Dec 2005 | $32.50 K(-90.5%) | $32.50 K(-90.5%) |
| Sep 2005 | - | $341.10 K(+0.1%) |
| Jun 2005 | - | $340.90 K(+0.1%) |
| Mar 2005 | - | $340.70 K(+0.1%) |
| Dec 2004 | $340.50 K(+0.2%) | $340.50 K(+0.1%) |
| Sep 2004 | - | $340.30 K(+0.0%) |
| Jun 2004 | - | $340.20 K(+0.1%) |
| Mar 2004 | - | $340.00 K |
| Dec 2003 | $339.80 K | - |
FAQ
- What is Sorrento Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Sorrento Therapeutics?
- What is Sorrento Therapeutics annual total liabilities year-on-year change?
- What is Sorrento Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Sorrento Therapeutics?
- What is Sorrento Therapeutics quarterly total liabilities year-on-year change?
What is Sorrento Therapeutics annual total liabilities?
The current annual total liabilities of SRNE is $494.51 M
What is the all time high annual total liabilities for Sorrento Therapeutics?
Sorrento Therapeutics all-time high annual total liabilities is $616.69 M
What is Sorrento Therapeutics annual total liabilities year-on-year change?
Over the past year, SRNE annual total liabilities has changed by -$122.18 M (-19.81%)
What is Sorrento Therapeutics quarterly total liabilities?
The current quarterly total liabilities of SRNE is $654.65 M
What is the all time high quarterly total liabilities for Sorrento Therapeutics?
Sorrento Therapeutics all-time high quarterly total liabilities is $654.65 M
What is Sorrento Therapeutics quarterly total liabilities year-on-year change?
Over the past year, SRNE quarterly total liabilities has changed by +$67.17 M (+11.43%)